License and Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jan. 31, 2020	Nov. 30, 2017	Dec. 31, 2020	Dec. 31, 2019
License Agreements [Line Items]
Research and development			$ 72,088,000	$ 30,911,000
Duke University
License Agreements [Line Items]
Sale of licensed products or services			0
Fees payment			300,000
Nonroyalty payment received			1,000,000.0	300,000
Wacker
License Agreements [Line Items]
Research and development			300,000	200,000
Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Research and development			100,000
License agreement upfront payment	$ 100,000
Minimum | Duke University
License Agreements [Line Items]
Aggregate royalties payment			200,000
Maximum | Achievement of Clinical Development and Regulatory Milestones | Duke University
License Agreements [Line Items]
Potential milestone payments			2,200,000
Maximum | Commercial Milestones | Duke University
License Agreements [Line Items]
Potential milestone payments			400,000
Maximum | Commercial Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestone payments	142,500,000
Maximum | Payment Upon Achievement of Certain Development and Intellectual Property Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestone payments	$ 5,100,000
MedImmune Limited
License Agreements [Line Items]
Milestone payments			$ 2,000,000.0	$ 1,000,000.0
MedImmune Limited | Maximum | Achievement of Clinical Development and Regulatory Milestones
License Agreements [Line Items]
Potential milestone payments		$ 15,000,000.0
MedImmune Limited | Maximum | Commercial Milestones
License Agreements [Line Items]
Potential milestone payments		$ 50,000,000.0